Cell-free nucleic acids as biomarkers in cancer patients

  title={Cell-free nucleic acids as biomarkers in cancer patients},
  author={Heidi Schwarzenbach and Dave S. B. Hoon and Klaus Pantel},
  journal={Nature Reviews Cancer},
DNA, mRNA and microRNA are released and circulate in the blood of cancer patients. Changes in the levels of circulating nucleic acids have been associated with tumour burden and malignant progression. In the past decade a wealth of information indicating the potential use of circulating nucleic acids for cancer screening, prognosis and monitoring of the efficacy of anticancer therapies has emerged. In this Review, we discuss these findings with a specific focus on the clinical utility of cell… 
Circulating nucleic acids as biomarkers in breast cancer
Assays that allow the repetitive monitoring of patients by using blood samples as liquid biopsy may be efficient in assessing cancer progression in patients whose tumor tissue is not available and may be excellent blood biomarkers for screening breast cancer.
Use of cell free DNA in breast oncology.
Circulating cell-free nucleic acids: promising biomarkers of hepatocellular carcinoma.
This work reviews the studies that evaluated cfNAs as circulating HCC biomarkers and discusses recent advances with regard to their diagnostic and prognostic significance.
DNA methylation signatures in circulating cell-free DNA as biomarkers for the early detection of cancer
The literature related to the use of serum or plasma circulating cell-free DNA for cancer diagnosis in the early stage and their power as future biomarkers are reviewed.
Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker
The current status of cell-free cTDNA including ctDNA biology, recently developed techniques for ct DNA detection, breast cancer specific detecting strategies, with a focus on clinical applications ofctDNA-based biomarkers in breast oncology are discussed.
Cell-free DNA as a diagnostic marker for cancer: current insights
A comprehensive evaluation of “liquid biopsy”, including cfDNA analysis, will be one of the critical challenges to better understand the early mechanisms of cancer development.
Circulating Cell-Free Nucleic Acids as Epigenetic Biomarkers in Precision Medicine
This review focuses on the novel approaches for exploring ccfNAs as epigenetic biomarkers in personalized clinical diagnosis and prognosis, their potential as therapeutic targets and disease progression monitors, and reveals the tremendous potential that epigenetics biomarkers present to improve precision medicine.
Life and death of circulating cell-free DNA
Tumor-specific, circulating cell-free DNA in liquid biopsies is a promising source of biomarkers for minimally invasive serial monitoring of treatment responses in cancer management and the role of circulating DNA in pathophysiological processes is reviewed.
Issues and Prospects of microRNA-Based Biomarkers in Blood and Other Body Fluids
The status of circulating miRNAs is reviewed, different analytical approaches are examined, and some of the challenges and opportunities are addressed.
Cell free nucleic acids as diagnostic and prognostic marker in leukemia
The findings of this study indicate that nucleic acids in circulation have a high diagnostic and prognostic value in leukemic patients and, thus, have the potential to be used alongside the usual methods in the management of this disease.


Circulating microRNAs as stable blood-based markers for cancer detection
It is shown here that miRNAs are present in human plasma in a remarkably stable form that is protected from endogenous RNase activity and established the measurement of tumor-derived mi RNAs in serum or plasma as an important approach for the blood-based detection of human cancer.
Circulating nucleic acids in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: state of the issue.
Two theories about metastatization are expound and integrate: the "genometastasis hypothesis" and the idea of stem cells as cancer stem cells.
Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis
The usefulness of circulating miRNA for cancer diagnosis, prognosis, and therapeutics is summarized and a mechanism for the secretion and incorporation of miRNA into the cells is proposed.
Circulating nucleic acids (CNAs) and cancer--a survey.
Extracellular DNA in Breast Cancer: Cell‐Surface‐Bound, Tumor‐Derived Extracellular DNA in Blood of Patients with Breast Cancer and Nonmalignant Tumors
Investigation of aberrant promoter methylation of RASSF1A and HIC‐1 genes in circulating extracellular DNA from the blood of breast cancer and fibroadenoma patients demonstrates that cell surface bound exDNA provides a valuable source of material for early noninvasive cancer diagnostics and monitoring.
Circulating Mitochondrial Nucleic Acids Have Prognostic Value for Survival in Patients with Advanced Prostate Cancer
In advanced prostate cancer patients, mtRNA seemed the strongest predictor of overall survival and an independent prognostic factor for cancer-related death and multivariate analysis indicates that mtRNA is an independent predictor of 2-year survival.
Detection and Monitoring of Cell‐Free DNA in Blood of Patients with Colorectal Cancer
Quantitative analysis demonstrates that elevated DNA levels can be detected in blood of patients with colorectal cancer and may be a useful tool in combination with other tumor markers for detection of coloreCTal cancer.
Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells.
The results indicate that plasma from cancer patients is able to transform cultured cells oncogenically, supporting the previously proposed hypothesis of genometastasis.
Circulating mutant DNA to assess tumor dynamics
It is found that ctDNA measurements could be used to reliably monitor tumor dynamics in subjects with cancer who were undergoing surgery or chemotherapy, and it is suggested that this personalized genetic approach could be generally applied to individuals with other types of cancer.
Circulating tumour cells in cancer patients: challenges and perspectives.